Oncology Today with Dr Neil Love

Featuring an interview with Dr Ramez Eskander, including the following topics:
Overview of antibody-drug conjugates (ADCs) and their role in the management of gynecologic cancers; considerations in sequencing (0:00)
Choosing between FRɑ- and HER2-directed ADCs for dually eligible patients; role of antigenic target in predicting efficacy benefit of ADCs (7:53)
Comparative efficacy and safety of ADCs and conventional chemotherapy (12:58)
Current and investigational targets of ADCs in gynecologic cancers (17:14)
Current research surrounding raludotatug deruxtecan (R-DXd) and its potential role in clinical practice (21:56)
Safety and tolerability profiles of ADCs, including R-DXd, and potential mitigation strategies (27:36)
Overview of available TROP2-directed ADCs for gynecologic cancers, including key clinical data (33:34)
Evolving use of TROP2-directed ADCs for gynecologic cancers in clinical trials (39:05)
Oral mucositis/stomatitis associated with TROP2-directed ADCs and potential mitigation strategies (44:38)

CME information and select publications

Featuring perspectives from Dr Joshua K Sabari, including the following topics:
Jänne PA et al. Final analysis results and patient-reported outcomes from DESTINY-Lung02 — A dose-blinded, randomized, phase 2 study of trastuzumab deruxtecan in patients with HER2-mutant metastatic NSCLC. J Thorac Oncol 2025;20(12):1814-28. (0:00)
Heymach JV et al. Circulating tumor DNA (ctDNA) analysis following zongertinib treatment (tx) in patients (pts) with human epidermal growth factor receptor 2 (HER2)-mutant non-small cell lung cancer (NSCLC): Phase Ia/Ib Beamion LUNG-1 study. ESMO 2025;Abstract 2020P. (8:30)
Schram AM et al. Beamion PANTUMOR-1: Rationale and design of a phase II trial of zongertinib in HER2-overexpressed/amplified or HER2-mutant solid tumors. Future Oncol 2026;22(7):795-803. (12:53)
Johnson ML et al. Beamion LUNG-2: A phase III randomized controlled trial of zongertinib (BI 1810631) versus standard of care in patients with locally advanced/metastatic non-squamous NSCLC harboring HER2 tyrosine kinase domain (TKD) mutations. ASCO 2024;Abstract TPS8654. (19:40)
Le X et al. SOHO-02: Phase III trial of BAY 2927088 in patients with locally advanced or metastatic NSCLC with HER2-activating mutations. ASCO 2025;Abstract TPS8648. (21:41)
Li BT et al. Open-label, randomized, multicenter, phase 3 study evaluating trastuzumab deruxtecan (T-DXd) as first-line treatment in patients with unresectable, locally advanced, or metastatic non-small cell lung cancer (NSCLC) harboring HER2 exon 19 or 20 mutations (DESTINY-Lung04). ASCO 2022;Abstract TPS9137. (22:59)
Jänne PA et al. Trastuzumab deruxtecan for ERBB2-mutant metastatic NSCLC with or without brain metastases: A secondary analysis of randomized clinical trials. JAMA Netw Open 2025;8(11):e2543107. (24:37)

CME information and select publications

Featuring perspectives from Dr Joshua K Sabari, including the following topics:
Heymach JV et al. Zongertinib in previously treated HER2-mutant non-small cell lung cancer. N Engl J Med 2025;392(23):2321-33. (0:00)
Popat S et al. Zongertinib as first-line treatment in patients with advanced HER2-mutant NSCLC: Beamion LUNG-1. ESMO 2025;Abstract LBA74. (5:25)
Le X et al. Sevabertinib in advanced HER2-mutant non-small cell lung cancer. N Engl J Med 2025;393(18):1819-32. (12:37)

CME information and select publications

Featuring perspectives from Ms Kelly Fischer, Dr Marissa Marti-Smith, Dr Rita Nanda and Dr Ruth M O'Regan, moderated by Dr Nanda, including the following topics:
Introduction (00:00)
Advent of CDK4/6 Inhibitors in HR-Positive Breast Cancer (BC) (1:24)
Risk Assessment for Patients with HR-Positive, HER2-Negative Localized BC (2:52)
Adjuvant CDK4/6 Inhibitor Therapy (17:14)
Practical Considerations with CDK4/6 Inhibitors (29:57)
Monitoring and Management of Cytopenias (42:02)
CDK4/6 Inhibitors in HR-Positive Metastatic BC (49:32)
Management of Gastrointestinal Adverse Events (1:03:47)
CDK4/6 Inhibitors in Unique Populations (1:10:41)
Rarer CDK4/6 Inhibitor-Associated Toxicities (1:19:48)

CME information and select publications

Featuring perspectives from Dr Tanios Bekaii-Saab, Dr Stacey A Cohen and Dr Arvind Dasari, moderated by Dr Bekaii-Saab, including the following topics:
Introduction (0:00)
Current and Future Role of Immune Checkpoint Inhibition in the Management of Microsatellite Instability-High/Mismatch Repair Deficient Localized and Locally Advanced Colorectal Cancer (CRC) — Dr Cohen (1:45)
Clinical Relevance and Practical Utilization of Molecular Residual Disease Analysis in CRC — Dr Dasari (34:08)
Recent Advances in Metastatic CRC: Optimizing Immunotherapy and Other Approaches — Dr Bekaii-Saab (1:00:42)

CME information and select publications